Report details the company’s commitment to improving healthcare through the power of genetic information and reveals fiscal 2023 environmental, social and governance initiatives
,
“At Invitae, sustainability is more than just a function; it is woven into the fabric of our DNA. We have used sustainability and ESG as catalysts for change,” said
The report provides an in-depth review of progress made on company-wide ESG measures over the past year. The company’s notable achievements include:
-
Expanding patient access and partnerships: We are focused on expanding access to genetic testing, developing policies, programs and guidelines to make more patients and their families eligible for testing. Since our founding, we have proudly served more than 4.6 million patients and in 2023 expanded our partnerships in rare diseases and data to advance drug discovery. -
Advancing genetic insights: We have enhanced our industry-leading variant classification and invitation generation capabilities through cutting-edge technologies such as machine learning and functional modeling. Since 2020, we’ve seen Invitae Generationtechnology’s uncertainty rate decrease by 40%. These tools allow us to continue to improve the accuracy of genetic insights. -
quality standards: We have obtained market authorizationUnited States (US) Food and Drug Administration (FDA) supporting one of our hereditary germline cancer panels is a testament to our rigorous standards and product quality. Our hereditary cancer team provides patients and their families with important information to make informed medical decisions. -
environmental sustainability: We have made progress in managing Scope 1 and Scope 2 greenhouse gas emissions and assessed the relevance of different Scope 3 categories in the value chain. We have also adopted an environmental policy at board level. Environmental sustainability is at the core of our ESG journey.
“I sincerely thank our outstanding team members for their dedication, hard work and focus on patients, as well as our greater mission of bringing genetic information into mainstream medicine and creating a healthier future for all,” he said.
about
To learn more, please visit invitation network and follow updatesLinkedIn, X, Instagramand Facebook @invite.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s ESG and sustainability plans and initiatives and their expected impact. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be relied upon as indicative of future performance.These risks and uncertainties include, but are not limited to: risks and uncertainties related to the Company’s ability to successfully complete its reorganization plan under Chapter 11; the Company’s ability to continue normal operations while the Chapter 11 proceedings are pending; Chapter 11 Potential adverse effects of the Chapter proceedings on the Company’s business, financial condition, liquidity and operating performance; The Company’s ability to use rapidly changing genetic data to accurately and consistently interpret test results; Risks related to litigation; Security breaches, loss of data and other disruption; laws and regulations applicable to the Company’s business; and other risks listed in the Company’s filings with regulatory authorities
Invite PR contact:
pr@invitae.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/invitae-publishes-its-environmental-social-and-governance-esg-report-302123530.html
source
#Invitae #releases #environmental #social #governance #ESG #reporting #company #announcement
Image Source : markets.ft.com